Fiala

Peptide library › Digestive health

Larazotide acetate

Also known as Larazotide, AT-1001

In clinical trialsDigestive health

Experimental gut peptide studied for coeliac disease, aiming to tighten a 'leaky' gut lining.

What people use it for

What Larazotide acetate does in the body

Designed to block zonulin signalling and help keep the tight junctions between gut-lining cells closed, so less gluten passes through.

Strength of evidence

Limited: early trials suggested symptom benefit, but a Phase 3 trial was stopped in 2022 after an interim analysis.

Look up the evidence

Live searches of official databases. New to the terms? See the glossary.

Reported side effects & risks

Who should avoid it or take extra care

Not a complete list. Check with a doctor or pharmacist about your own health and medicines.

Regulatory status

Investigational. Not approved by the FDA.

How it's taken

Route: Capsule by mouth, before meals (in trials)

How long it lasts (half-life): Not relevant: designed to work inside the gut

Latest research & news

Picked automatically from PubMed, ClinicalTrials.gov and the FDA, and updated daily. Early, lab and animal studies often don't carry over to people.

Keep track of Larazotide acetate privately

Fiala is a free app for logging doses, tracking vials and setting reminders. No account, and everything you log stays on your phone.

Open Larazotide acetate in Fiala How to install
Not medical advice. This page is general education. Talk to a qualified clinician before starting, stopping or changing any treatment.

More in Digestive health